Auranofin versus placebo in rheumatoid arthritis

Abstract

BackgroundAuranofin is an oral gold compound used for the treatment of rheumatoid arthritis (RA). The use of auranofin has declined in the past few years, perhaps due in part to conflicting results from di erent studies. ObjectivesTo estimate the short-term e icacy and toxicity of auranofin for the treatment of (RA) Search methodsAn electronic literature search was conducted using MEDLINE and EMBASE, followed by hand searches of the reference lists of the trials retrieved from the electronic search. Selection criteriaAll randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing auranofin against placebo in patients with RA Data collection and analysisThe methodological quality of the trials was assessed using Jadad's score. Rheumatoid arthritis outcome measures were extracted from the publications for the 6-month endpoint. The pooled analysis was performed using standardized mean di erences (SMDs) for joint counts, pain and global assessments. The weighted mean di erence (WMD) was used for ESR. Toxicity was evaluated with pooled odds ratios for withdrawals and adverse reactions. A chi-square test was used to assess heterogeneity among trials. Fixed e ects models were used throughout. Auranofin versus placebo in rheumatoid arthritis (Review)

Systematic review of rheumatoid arthritis patient education

“…The most important benefit was for functional disability, with an effect size of −0.17. This compares with the following effect sizes for disease‐modifying drug treatments: −0.09 (95% CI −0.45, 0.27) for antimalarials (95); −0.19 (95% CI −0.39, 0.02) for auranofin (96); −0.29 (95% CI −0.77, 0.19) for penicillamine (97); −0.31 (95% CI −1.06, 0.44) for azathioprine (98); −0.78 (95% CI −1.10, −0.47) for cyclosporine (99); and −1.48 (95% CI −1.82, −1.14) for methotrexate (100). Glucocorticoids, when given in addition to disease‐modifying drugs, have an additional effect size of −0.57 (95% CI −0.92, −0.22) (101).…”

Systematic review of rheumatoid arthritis patient education

“…The most important benefit was for functional disability, with an effect size of −0.17. This compares with the following effect sizes for disease‐modifying drug treatments: −0.09 (95% CI −0.45, 0.27) for antimalarials (95); −0.19 (95% CI −0.39, 0.02) for auranofin (96); −0.29 (95% CI −0.77, 0.19) for penicillamine (97); −0.31 (95% CI −1.06, 0.44) for azathioprine (98); −0.78 (95% CI −1.10, −0.47) for cyclosporine (99); and −1.48 (95% CI −1.82, −1.14) for methotrexate (100). Glucocorticoids, when given in addition to disease‐modifying drugs, have an additional effect size of −0.57 (95% CI −0.92, −0.22) (101).…”

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

“…With the discovery that RSL3 likely functions through pan-inhibition of the selenoproteome, we next sought to investigate the therapeutic potential of Auranofin. Auranofin is an orally bioavailable gold salt that is FDA approved for the treatment of rheumatoid arthritis 41,42 . Auranofin is a compound S -glycosyl gold salt, comprised of a 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranose sugar with the sulfur atom coordinated to a (triethylphosphoranylidene)gold functional group.…”

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

“…However, auranofin has been used extensively, and its safety is well documented (49). Auranofin is approved for long-term daily dosage at 6 mg/day, and serious side effects are rare, the most common being gastrointestinal distress that is easily manageable (50). Patients on auranofin therapy have been monitored in clinical trials for longer than 5 years, a much greater interval than would be expected for a normal course of antibiotic therapy or even drugresistant TB cases, and have shown no cumulative toxicity (51).…”

Systematic review of rheumatoid arthritis patient education

“…The most important benefit was for functional disability, with an effect size of −0.17. This compares with the following effect sizes for disease‐modifying drug treatments: −0.09 (95% CI −0.45, 0.27) for antimalarials (95); −0.19 (95% CI −0.39, 0.02) for auranofin (96); −0.29 (95% CI −0.77, 0.19) for penicillamine (97); −0.31 (95% CI −1.06, 0.44) for azathioprine (98); −0.78 (95% CI −1.10, −0.47) for cyclosporine (99); and −1.48 (95% CI −1.82, −1.14) for methotrexate (100). Glucocorticoids, when given in addition to disease‐modifying drugs, have an additional effect size of −0.57 (95% CI −0.92, −0.22) (101).…”

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

“…With the discovery that RSL3 likely functions through pan-inhibition of the selenoproteome, we next sought to investigate the therapeutic potential of Auranofin. Auranofin is an orally bioavailable gold salt that is FDA approved for the treatment of rheumatoid arthritis 41,42 . Auranofin is a compound S -glycosyl gold salt, comprised of a 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranose sugar with the sulfur atom coordinated to a (triethylphosphoranylidene)gold functional group.…”

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

“…However, auranofin has been used extensively, and its safety is well documented (49). Auranofin is approved for long-term daily dosage at 6 mg/day, and serious side effects are rare, the most common being gastrointestinal distress that is easily manageable (50). Patients on auranofin therapy have been monitored in clinical trials for longer than 5 years, a much greater interval than would be expected for a normal course of antibiotic therapy or even drugresistant TB cases, and have shown no cumulative toxicity (51).…”

Systematic review of rheumatoid arthritis patient education

“…The most important benefit was for functional disability, with an effect size of −0.17. This compares with the following effect sizes for disease‐modifying drug treatments: −0.09 (95% CI −0.45, 0.27) for antimalarials (95); −0.19 (95% CI −0.39, 0.02) for auranofin (96); −0.29 (95% CI −0.77, 0.19) for penicillamine (97); −0.31 (95% CI −1.06, 0.44) for azathioprine (98); −0.78 (95% CI −1.10, −0.47) for cyclosporine (99); and −1.48 (95% CI −1.82, −1.14) for methotrexate (100). Glucocorticoids, when given in addition to disease‐modifying drugs, have an additional effect size of −0.57 (95% CI −0.92, −0.22) (101).…”

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

“…With the discovery that RSL3 likely functions through pan-inhibition of the selenoproteome, we next sought to investigate the therapeutic potential of Auranofin. Auranofin is an orally bioavailable gold salt that is FDA approved for the treatment of rheumatoid arthritis 41,42 . Auranofin is a compound S -glycosyl gold salt, comprised of a 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranose sugar with the sulfur atom coordinated to a (triethylphosphoranylidene)gold functional group.…”

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

“…However, auranofin has been used extensively, and its safety is well documented (49). Auranofin is approved for long-term daily dosage at 6 mg/day, and serious side effects are rare, the most common being gastrointestinal distress that is easily manageable (50). Patients on auranofin therapy have been monitored in clinical trials for longer than 5 years, a much greater interval than would be expected for a normal course of antibiotic therapy or even drugresistant TB cases, and have shown no cumulative toxicity (51).…”